bpc-157 subcutaneous or intramuscular Peptide bpc-157 injection subcutaneous vs intramuscular
Description
A 2025 narrative review of musculoskeletal research described both the regenerative findings and the open questions about translation to human clinical use (PMID 40789979)
KLOW can begin roughly 4872 hours after minor procedures, once the initial inflammatory cascade has peaked, with any new compounds held through the acute first week
some peptide reaches systemic circulation (supported by systemic effect reports) but at likely reduced bioavailability compared to parenteral
They send signals to the brain
